An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202.
Saved in:
| Title: | An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202. |
|---|---|
| Authors: | Vogel A; Hannover Medical School, Hannover, Germany; Toronto General Hospital, Toronto; Princess Margaret Cancer Centre, Toronto, Canada. Electronic address: vogela@me.com., Sahai V; University of Michigan, Ann Arbor, USA., Hollebecque A; Gustave Roussy Cancer Center, Paris, France., Vaccaro GM; Providence Cancer Center, Portland, USA., Melisi D; Università degli studi di Verona, Verona, Italy., Al Rajabi RM; University of Kansas Medical Center, Kansas City., Paulson AS; Baylor University Medical Center, Dallas., Borad MJ; Mayo Clinic Cancer Center, Phoenix., Gallinson D; Morristown Memorial Hospital, Morristown., Murphy AG; Johns Hopkins University School of Medicine, Baltimore, USA., Oh DY; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, Republic of Korea., Dotan E; Fox Chase Cancer Center, Philadelphia., Catenacci DV; University of Chicago Medicine, Chicago, USA., Van Cutsem E; University Hospitals Gasthuisberg, Leuven & University of Leuven, Leuven, Belgium., Lihou CF; Incyte Corporation, Wilmington, USA., Zhen H; Incyte Corporation, Wilmington, USA., Veronese ML; Incyte International Biosciences Sàrl, Morges, Switzerland., Abou-Alfa GK; Memorial Sloan Kettering Cancer Center, New York; Weill Medical College at Cornell University, New York, USA; Trinity College Dublin School of Medicine, Dublin, Ireland. |
| Source: | ESMO open [ESMO Open] 2024 Jun; Vol. 9 (6), pp. 103488. Date of Electronic Publication: 2024 Jun 04. |
| Publication Type: | Journal Article; Multicenter Study; Clinical Trial, Phase II |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 38838500 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Vogel+A%22">Vogel A</searchLink>; Hannover Medical School, Hannover, Germany; Toronto General Hospital, Toronto; Princess Margaret Cancer Centre, Toronto, Canada. Electronic address: vogela@me.com.<br /><searchLink fieldCode="AU" term="%22Sahai+V%22">Sahai V</searchLink>; University of Michigan, Ann Arbor, USA.<br /><searchLink fieldCode="AU" term="%22Hollebecque+A%22">Hollebecque A</searchLink>; Gustave Roussy Cancer Center, Paris, France.<br /><searchLink fieldCode="AU" term="%22Vaccaro+GM%22">Vaccaro GM</searchLink>; Providence Cancer Center, Portland, USA.<br /><searchLink fieldCode="AU" term="%22Melisi+D%22">Melisi D</searchLink>; Università degli studi di Verona, Verona, Italy.<br /><searchLink fieldCode="AU" term="%22Al+Rajabi+RM%22">Al Rajabi RM</searchLink>; University of Kansas Medical Center, Kansas City.<br /><searchLink fieldCode="AU" term="%22Paulson+AS%22">Paulson AS</searchLink>; Baylor University Medical Center, Dallas.<br /><searchLink fieldCode="AU" term="%22Borad+MJ%22">Borad MJ</searchLink>; Mayo Clinic Cancer Center, Phoenix.<br /><searchLink fieldCode="AU" term="%22Gallinson+D%22">Gallinson D</searchLink>; Morristown Memorial Hospital, Morristown.<br /><searchLink fieldCode="AU" term="%22Murphy+AG%22">Murphy AG</searchLink>; Johns Hopkins University School of Medicine, Baltimore, USA.<br /><searchLink fieldCode="AU" term="%22Oh+DY%22">Oh DY</searchLink>; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Dotan+E%22">Dotan E</searchLink>; Fox Chase Cancer Center, Philadelphia.<br /><searchLink fieldCode="AU" term="%22Catenacci+DV%22">Catenacci DV</searchLink>; University of Chicago Medicine, Chicago, USA.<br /><searchLink fieldCode="AU" term="%22Van+Cutsem+E%22">Van Cutsem E</searchLink>; University Hospitals Gasthuisberg, Leuven & University of Leuven, Leuven, Belgium.<br /><searchLink fieldCode="AU" term="%22Lihou+CF%22">Lihou CF</searchLink>; Incyte Corporation, Wilmington, USA.<br /><searchLink fieldCode="AU" term="%22Zhen+H%22">Zhen H</searchLink>; Incyte Corporation, Wilmington, USA.<br /><searchLink fieldCode="AU" term="%22Veronese+ML%22">Veronese ML</searchLink>; Incyte International Biosciences Sàrl, Morges, Switzerland.<br /><searchLink fieldCode="AU" term="%22Abou-Alfa+GK%22">Abou-Alfa GK</searchLink>; Memorial Sloan Kettering Cancer Center, New York; Weill Medical College at Cornell University, New York, USA; Trinity College Dublin School of Medicine, Dublin, Ireland. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101690685%22">ESMO open</searchLink> [ESMO Open] 2024 Jun; Vol. 9 (6), pp. 103488. <i>Date of Electronic Publication: </i>2024 Jun 04. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Multicenter Study; Clinical Trial, Phase II – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101690685 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2059-7029 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220597029%22">20597029 </searchLink><i>NLM ISO Abbreviation: </i>ESMO Open <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38838500 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.esmoop.2024.103488 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 103488 Titles: – TitleFull: An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Vogel A – PersonEntity: Name: NameFull: Sahai V – PersonEntity: Name: NameFull: Hollebecque A – PersonEntity: Name: NameFull: Vaccaro GM – PersonEntity: Name: NameFull: Melisi D – PersonEntity: Name: NameFull: Al Rajabi RM – PersonEntity: Name: NameFull: Paulson AS – PersonEntity: Name: NameFull: Borad MJ – PersonEntity: Name: NameFull: Gallinson D – PersonEntity: Name: NameFull: Murphy AG – PersonEntity: Name: NameFull: Oh DY – PersonEntity: Name: NameFull: Dotan E – PersonEntity: Name: NameFull: Catenacci DV – PersonEntity: Name: NameFull: Van Cutsem E – PersonEntity: Name: NameFull: Lihou CF – PersonEntity: Name: NameFull: Zhen H – PersonEntity: Name: NameFull: Veronese ML – PersonEntity: Name: NameFull: Abou-Alfa GK IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 06 Text: 2024 Jun Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 2059-7029 Numbering: – Type: volume Value: 9 – Type: issue Value: 6 Titles: – TitleFull: ESMO open Type: main |
| ResultId | 1 |